BCDA (BioCardia) Debt-to-Asset : 0.06 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCDA BioCardia Inc BCDA
23 GF Score
Price $1.01
! 1 Warning Sign
View Full Analysis

What is BioCardia Debt-to-Asset?

BioCardia BCDA -0.50% 23 Debt-to-Asset is 0.06 as of Jun. 2026. GuruFocus rates BCDA with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

BioCardia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.29 Mil. BioCardia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. BioCardia's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $4.76 Mil. BioCardia's debt to asset for the quarter that ended in Jun. 2026 was 0.06.

BioCardia  (NAS:BCDA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BioCardia Debt-to-Asset Related Terms

BioCardia Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for BioCardia's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCardia Debt-to-Asset Chart

BioCardia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.17 0.44 0.26 0.16

BioCardia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.10 0.16 0.24 0.06

BCDA vs SNTI, COCP, ZEOX: Debt-to-Asset Comparison

For the Biotechnology subindustry, BioCardia's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCardia Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioCardia's Debt-to-Asset falls into.


BCDA
23GF Score
BioCardia Inc BCDA
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCardia Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioCardia's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.442 + 0.086) / 3.413
=0.15

BioCardia's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.293 + 0) / 4.755
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.06 mean?
BioCardia (BCDA) has a Debt-to-Asset of 0.06 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BioCardia and its competitors.
Is BioCardia's Debt-to-Asset too high?
BioCardia's current Debt-to-Asset is 0.06. Overall, BioCardia has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's Debt-to-Asset compare to SNTI and COCP?
BioCardia's Debt-to-Asset of 0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BioCardia and its competitors. BioCardia's current Debt-to-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (BCDA) has a current Debt-to-Asset of 0.06. The current Debt-to-Asset is 0.06. BioCardia's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For BioCardia (BCDA), the current Debt-to-Asset is 0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioCardia Business Description

Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
23GF Score

Get the complete analysis for BCDA

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price